Book a Meeting

Anti-TIGIT Antibody, ADCC Enchanced (BioBet-CB-093LX) (CAT#: BioBet-CB-093LX) Datasheet

Target
TIGIT
Isotype
IgG1
Description
Anti-TIGIT Antibody, ADCC Enchanced (BioBet-CB-093LX) is a glycosylation-modified anti-TIGIT therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TIGIT antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TIGIT
Full Name
T cell immunoreceptor with Ig and ITIM domains
Background
This gene encodes a member of the PVR (poliovirus receptor) family of immunoglobin proteins. The product of this gene is expressed on several classes of T cells including follicular B helper T cells (TFH). The protein has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses.[provided by RefSeq, Sep 2009]
Alternative Names
T cell immunoreceptor with Ig and ITIM domains; VSIG9; VSTM3; WUCAM; TIGIT
Gene ID
201633
UniProt ID
Q495A1
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-093LX
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human TIGIT (Tiragolumab) Antibody is derived from clone Tiragolumab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the TIGIT, and it is intended for the research of Small cell lung cancer .
Antibody Indication
Small cell lung cancer

Small cell lung cancer

Related Products

Anti-TIGIT Antibody, Non-Fucosylated (BioBet-1731ZP) (CAT#: BioBet-1731ZP)
Anti-TIGIT Antibody, On-Target (AES-0622-ZP771) (CAT#: AES-0622-ZP771)
Anti-TIGIT Antibody, Recycling (AES-0622-ZP115) (CAT#: AES-0622-ZP115)
Anti-TIGIT Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP443) (CAT#: AES-0622-ZP443)
Anti-TIGIT Antibody, Half-Life Extended (AES-0622-ZP1099) (CAT#: AES-0622-ZP1099)
Anti-TIGIT Antibody, Non-Fucosylated (BioBet-1730ZP) (CAT#: BioBet-1730ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.